GlassScriptPhysician profile
Michele A Scott
NPI 1003888769
$2,744.02
in general payments reported to CMS, 2019-2025
36 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $152 · 2021: $240 · 2022: $401 · 2023: $361 · 2024: $658 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $499.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $417.13 | 2021-2025 | Linzess, Vraylar |
| Glaxosmithkline, LLC. | $282.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $277.97 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $130.83 | 2019-2024 | |
| Amgen INC. | $93.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $87.71 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Pfizer INC. | $80.25 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $75.40 | 2022-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.93 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $65.68 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $59.40 | 2020-2025 | Airsupra |
| Nestle Healthcare Nutrition INC. | $52.48 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.28 | 2021-2024 | |
| Dynavax Technologies Corporation | $39.78 | 2024 | Heplisav-B |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $38.09 | 2024 | Nuzyra |
| Abbott Laboratories | $33.80 | 2022-2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $31.97 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.69 | 2021-2023 | |
| Ardelyx, INC. | $29.91 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $27.72 | 2022 | |
| Axsome Therapeutics, INC. | $27.03 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $24.12 | 2022 | |
| Averitas Pharma INC. | $23.60 | 2025 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $22.91 | 2022 | |
| Genentech USA, INC. | $19.73 | 2020 | |
| Exact Sciences Corporation | $17.97 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $17.14 | 2023 | Rexulti |
| Upsher-Smith Laboratories LLC | $16.27 | 2021 | |
| Eisai INC. | $15.75 | 2021 | |
| Cashflow Solutions, LLC | $15.07 | 2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Renalytix Ai, INC. | $14.80 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Phadia US INC. | $14.44 | 2020 | |
| Astellas Pharma US INC | $13.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.16 | 2019 | |
| Hikma Pharmaceuticals USA | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.